Adventitious agent testing is critical to ensure patient safety and maintain product integrity. Biopharmaceuticals, often derived from living cells, are susceptible to contamination by viruses and mycoplasmas, which can be introduced during cell culture, raw material handling, or manufacturing processes. Viral contamination can pose serious health risks, including infection or immune responses in patients, while mycoplasmas—tiny bacteria lacking cell walls—can alter cellular functions, compromise product efficacy, and skew quality control results. Rigorous testing helps detect and eliminate these contaminants…
